CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
CTL-associated antigen 4 (CTLA4) blockade releases inhibitory controls on T cell activation and proliferation, inducing antitumor immunity in both preclinical and early clinical trials. We examined the mechanisms of action of anti-CTLA4 and a GM-CSF-transduced tumor cell vaccine (Gvax) and their impact on the balance of effector T cells (Teffs) and Tregs in an in vivo model of B16/BL6 melanoma. Tumor challenge increased the frequency of Tregs in lymph nodes, and untreated tumors became infiltrated by CD4+Foxp3- and CD4+Foxp3+ T cells but few CD8+ T cells. Anti-CTLA4 did not deplete Tregs or permanently impair their function but acted in a cell-intrinsic manner on both Tregs and Teffs, allowing them to expand, most likely in response to self antigen. While Gvax primed the tumor-reactive Teff compartment, inducing activation, tumor infiltration, and a delay in tumor growth, the combination with CTLA4 blockade induced greater infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly correlated with tumor rejection. The data suggest that Tregs control both CD4+ and CD8+ T cell activity within the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonstrate inversion of the ratio and correlation with tumor rejection during Gvax/anti-CTLA4 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Quezada et al., 2006
Experimental — accuracy not yet measuredIn the citing paper
“Mouse melanoma models, for example, have shown that the combination of anti-CTLA-4 with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or with agonistic antibodies targeting costimulatory receptors such as CD40, increased tumor rejection in a synergistic manner (121, 122).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [121]
In the citing paper
“In general, anti-CTLA4 expands CD4 effector T cells (Teff) with subsequent increase in the Teff/ Treg ratio in responding tumors (22).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 101–200 of 697
Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R., & Allison, J. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080099 · Cited by 218
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 215
Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A., & Allison, J. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019499 · Cited by 213
“Combination therapy yielded highly advantageous ratios of intra-tumoral CD8+ and CD4+ effector T-cells relative to Tregs which often correlates with rejection in this system [4,16].”
BackgroundRalf Paus, L., Schallreuter, K. U., Bahadoran, P., Picardo, M., Slominski, A., Elassiuty, Y. E., Kemp, E. H., Giachino, C., Liu, J. B., Luiten, R. M., et al. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00666_1.x · Cited by 211
Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
Kaufman, H. L., Ruby, C. E., Hughes, T., & Slingluff, C. L. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-11 · Cited by 212
“Antibodies that block the co-inhibitory T-cell molecules CTLA-4 and PD-1 plus GM-CSF have boosted immune responses against melanomas [5,27-31].”
BackgroundYu, P., Steel, J. C., Zhang, M., Morris, J. C., & Waldmann, T. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1966 · Cited by 213
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Cheng, W., Kang, K., Zhao, A., & Wu, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01581-2 · Cited by 204
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205
Guo, Z., Wang, X., Cheng, D., Xia, Z., Luan, M., & Zhang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089350 · Cited by 207
“immunosuppressive cells which is closely related with the effective immunotherapy as previously stated [41,42].”
Preston, C. C., Maurer, M. J., Oberg, A. L., Visscher, D. W., Kalli, K. R., Hartmann, L. C., Goode, E. L., & Knutson, K. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080063 · Cited by 208
“Alternatively, Quezada and colleagues show that checkpoint anti-CTLA-4 blockade in combination with vaccine therapy could also be effective at altering the balance without eliminating Tregs, suggesting a potential usage for the recently approved anti-human CTLA-4 antibody in ovarian cancer [33,34].”
BackgroundSolomon, I., Amann, M., Goubier, A., Arce Vargas, F., Zervas, D., Qing, C., Henry, J. Y., Ghorani, E., Akarca, A. U., Marafioti, T., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00133-0 · Cited by 204
Van Damme, H., Dombrecht, B., Kiss, M., Roose, H., Allen, E., Van Overmeire, E., Kancheva, D., Martens, L., Murgaski, A., Bardet, P. M. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001749 · Cited by 205
Liu, X.-D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., German, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 204
“Blockade of CTL-associated antigen 4 (CTLA-4) in melanoma patients and in a mouse model shifted the ratio of effector T cells to Tregs by around 5-fold and consequently led to tumor regression (19, 20).”
BackgroundIncreased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy
Ng Tang, D., Shen, Y., Sun, J., Wen, S., Wolchok, J. D., Yuan, J., Allison, J. P., & Sharma, P. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0020 · Cited by 203
“Also, since pre-clinical data suggest that combination therapies with agents that prime a T-cell response plus anti-CTLA-4 are more effective at eliciting anti-tumor responses as compared to monotherapy (24-26), clinical trials are underway with anti-CTLA-4 in various combination strategies, which will require appropr…”
BackgroundSelf-citationPentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
“A recent analysis of the effects of the combination therapy of GM-CSF and anti-CTLA-4 antibodies on the effector and regulatory T-cell compartments in the B16 mouse model of melanoma has shown that the treatment acts via a cell-autonomous mechanism on both kinds of T cells, allowing them to expand without depleting or…”
BackgroundHydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity
Li, Y., Fang, M., Zhang, J., Wang, J., Song, Y., Shi, J., Li, W., Wu, G., Ren, J., Wang, Z., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1074374 · Cited by 203
Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 202
T cell pathology in skin inflammation
Sabat, R., Wolk, K., Loyal, L., Döcke, W.-D., & Ghoreschi, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00742-7 · Cited by 201
“Vice versa, the parameter that best correlates with favorable clinical outcome and survival of melanoma patients seems to be the ratio of CD8-positive effector T cells to Treg cells in the tumor microenvironment [173].”
BackgroundThe Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy
Vasievich, E. A., & Huang, L. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1004228 · Cited by 199
Suppression, subversion and escape: the role of regulatory T cells in cancer progression
Oleinika, K., Nibbs, R. J., Graham, G. J., & Fraser, A. R. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2012.04657.x · Cited by 198
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A., & Tötterman, T. H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c01fcb · Cited by 198
Human regulatory T cells induce T-lymphocyte senescence
Ye, J., Huang, X., Hsueh, E. C., Zhang, Q., Ma, C., Zhang, Y., Varvares, M. A., Hoft, D. F., & Peng, G. (2012) · Blood · doi:10.1182/blood-2012-03-416040 · Cited by 198
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
Kwong, B., Gai, S. A., Elkhader, J., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 197
“Lip-aCD137 þ Lip-IL-2Fc therapy clearly blocked Treg accumulation within treated tumors and significantly enhanced tumor-infiltrating CTL:Treg ratios, a measure known to correlate with favorable antitumor immunity (48).”
Jinushi, M., Nakazaki, Y., Dougan, M., Carrasco, D. R., Mihm, M., & Dranoff, G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30966 · Cited by 195
“Under steady-state conditions, GM-CSF induced MFG-E8 expression on antigen-presenting cells, resulting in the efficient phagocytosis of apoptotic cells, the maintenance of Tregs in the periphery, and the suppression of autoreactive Th1 and Th17 cells.”
BackgroundInfluentialMartinet, L., Le Guellec, S., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J.-P. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 193
Park, Y.-J., Kuen, D.-S., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 194
Recent Progress in GM-CSF-Based Cancer Immunotherapy
Yan, W.-L., Shen, K.-Y., Tien, C.-Y., Chen, Y.-A., & Liu, S.-J. (2017) · Immunotherapy · doi:10.2217/imt-2016-0141 · Cited by 191
Li, B., VanRoey, M., Wang, C., Chen, T.-H. T., Korman, A., & Jooss, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1825 · Cited by 191
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau3259 · Cited by 190
“As a consequence, CBD-CPI treatment enhanced effector (CD62L−CD44+) CD8+ T cell–to-Treg ratios within the tumor, a predictor of therapeutic efficacy (32), compared to equidosed unmodified CPI and PBS treatments (Fig.”
BackgroundSuppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
“Consistent with previous data indicating that anti–CTLA-4 mAb in combination with vaccination, but not as monotherapy, results in increased intratumoral T cell infiltration (44), only the combination of IR and 9H10 resulted in a significant increase (P < 0.”
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Terranova-Barberio, M., Pawlowska, N., Dhawan, M., Moasser, M., Chien, A. J., Melisko, M. E., Rugo, H., Rahimi, R., Deal, T., Daud, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17414-y · Cited by 177
Lu, L., Xu, X., Zhang, B., Zhang, R., Ji, H., & Wang, X. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-36 · Cited by 177
“Analyzing the components of TAC from treated mice, we found that single GITR triggering slightly increased or decreased the percentages of CD4 and CD8 T cells or Treg and MDSC respectively in this tumor model, which is consistent with previous reporting effects of GITR triggering on these subsets [31,32]; although sin…”
ResultCTLA‐4: a key regulatory point in the control of autoimmune disease
Scalapino, K. J., & Daikh, D. I. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00639.x · Cited by 176
“Blocking CTLA-4 with monoclonal anti-CTLA-4 antibody in a model of malignant melanoma model not only results in increased T-cell tumor infiltration in vivo, but also increased infiltration by Tregs (69).”
BackgroundIn situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille-Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 177
Banerjee, T., DuHadaway, J. B., Gaspari, P., Sutanto-Ward, E., Munn, D. H., Mellor, A. L., Malachowski, W. P., Prendergast, G. C., & Muller, A. J. (2008) · Oncogene · doi:10.1038/sj.onc.1210939 · Cited by 175
“However, in the B16-F10 tumor model, CTLA4 monoclonal antibody blockade failed to elicit a single agent response, (although it produced significant autoimmunity), effecting tumor growth suppression only when administered in conjunction with a granulocyte-macrophage colonystimulating factor transduced tumor cell vaccin…”
BackgroundDevelopment of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Nimmerjahn, F., Gordan, S., & Lux, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.005 · Cited by 172
Arensman, M. D., Yang, X. S., Leahy, D. M., Toral-Barza, L., Mileski, M., Rosfjord, E. C., Wang, F., Deng, S., Myers, J. S., Abraham, R. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814932116 · Cited by 171
“6A), anti–CTLA-4 significantly boosted the intratumoral ratio of CD4 T effectors (Teffs) to Treg cells, a positive indicator of anti–CTLA-4 efficacy against tumors (32), in both WT and xCT mice (Fig.”
BackgroundKatz, S. C., Bamboat, Z. M., Maker, A. V., Shia, J., Pillarisetty, V. G., Yopp, A. C., Hedvat, C. V., Gonen, M., Jarnagin, W. R., Fong, Y., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2668-9 · Cited by 171
“The functional importance of Treg lies in their ability to interact with and suppress helper CD4 and cytotoxic CD8 T cells.(20,31,32) As such, we analyzed ratios of Treg to CD4 and CD8 T cells.”
BackgroundTissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A. S., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
“The ratio of effector T cells (Eff T cells) to Tregs is associated with response to anti-CTLA-4 checkpoint blockade therapy, where higher Tregs are associated with decreased efficacy (42, 43).”
BackgroundWhole Cell Vaccines—Past Progress and Future Strategies
Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 165
Stagg, J., & Allard, B. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012475152 · Cited by 166
“Anti-CTLA-4 mAb therapy enhances the antitumor function of CD8+ T cells, increases the ratio of CD8+ T cells to Foxp3+ T regulatory cells, and inhibits the suppressive function of T regulatory cells [Quezada et al. 2006].”
BackgroundSong, X.-T., Kabler, K. E., Shen, L., Rollins, L., Huang, X. F., & Chen, S.-Y. (2008) · Nature Medicine · doi:10.1038/nm1721 · Cited by 163
“Alternatively, antagonist antibodies to cytotoxic T lymphocyte antigen-4 or agonist antibodies to glucocorticoid-induced tumor necrosis factor receptor (GITR) can overcome T reg cell–mediated suppression by overactivating CTL”
BackgroundExpansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
Hall, M., Liu, H., Malafa, M., Centeno, B., Hodul, P. J., Pimiento, J., Pilon-Thomas, S., & Sarnaik, A. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0164-7 · Cited by 162
“T cells localized to the pancreatic tumor microenvir-onment have long been characterized as both intrinsically and extrinsically suppressed, frequently attributed to the presence of T regs [14, 37, 38].”
BackgroundStructural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
Ramagopal, U. A., Liu, W., Garrett-Thomson, S. C., Bonanno, J. B., Yan, Q., Srinivasan, M., Wong, S. C., Bell, A., Mankikar, S., Rangan, V. S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617941114 · Cited by 162
“Blockade of CTLA-4 also promotes Treg suppression in vitro (6, 19).”
BackgroundHannani, D., Vétizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaib, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.3 · Cited by 162
TLR8 signaling enhances tumor immunity by preventing tumor‐induced T‐cell senescence
Ye, J., Ma, C., Hsueh, E. C., Dou, J., Mo, W., Liu, S., Han, B., Huang, Y., Zhang, Y., Varvares, M. A., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403918 · Cited by 161
“However, these strategies can concurrently eliminate activated effector T cells, prevent effector T-cell activities, and induce Treg cell replenishment, which attenuate the effects of effector T cells on anti-tumor immunity (Colombo & Piconese, 2007; Powell et al , 2007a,b; Quezada et al , 2006).”
Hirschhorn-Cymerman, D., Budhu, S., Kitano, S., Liu, C., Zhao, F., Zhong, H., Lesokhin, A. M., Avogadri-Connors, F., Yuan, J., Li, Y., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120532 · Cited by 159
“…alShamkhani et al., 1996), FGK45 (anti CD40; Rolink et al., 1996), and DTA1 (antiGITR; Ko et al., 2005) were produced and purified by the Monoclonal Antibody Core Facility at MSKCC. 9D9 (anti–CTLA4; Quezada et al., 2006) and 10F.9G2 (anti– PDL1; Eppihimer et al., 2002) were purchased from BioXcell.”
MethodHSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Mbofung, R. M., McKenzie, J. A., Malu, S., Zhang, M., Peng, W., Liu, C., Kuiatse, I., Tieu, T., Williams, L., Devi, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00449-z · Cited by 159
Self-citationHogan, S. A., Courtier, A., Cheng, P. F., Jaberg-Bentele, N. F., Goldinger, S. M., Manuel, M., Perez, S., Plantier, N., Mouret, J.-F., Nguyen-Kim, T. D. L., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0136 · Cited by 155
“memory T cells (29) and depletes regulatory T cells (Treg) in the tumor microenvironment (30), leading to an increase in the effector T-cell/Treg ratio at the tumor site (31).”
BackgroundSTAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer
Oweida, A. J., Darragh, L., Phan, A., Binder, D., Bhatia, S., Mueller, A., Court, B. V., Milner, D., Raben, D., Woessner, R., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz036 · Cited by 156
Schmidt, E. M., Wang, C. J., Ryan, G. A., Clough, L. E., Qureshi, O. S., Goodall, M., Abbas, A. K., Sharpe, A. H., Sansom, D. M., & Walker, L. S. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.274 · Cited by 155
“In this respect, CTLA-4 blockade has recently been shown to increase Treg numbers in a mouse melanoma model (31) and in prostate cancer patients (32).”
BackgroundResultTsujikawa, T., Crocenzi, T. S., Durham, J. N., Sugar, E. A., Wu, A. A., Onners, B., Nauroth, J. M., Anders, R. A., Fertig, E. J., Laheru, D. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3978 · Cited by 172
“Key results looked at the longitudinal change in cytokine expression profiles based on: (1) trial arm and (2) OS.”
BackgroundMethodInfluentialCyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
Wada, S., Yoshimura, K., Hipkiss, E. L., Harris, T. J., Yen, H.-R., Goldberg, M. V., Grosso, J. F., Getnet, D., Demarzo, A. M., Netto, G. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4102 · Cited by 152
“Recent studies suggested that treatment effects in mice treated with a combination of GVAX and anti-CTLA4 seemed to correlate with increases in the ratio of effector cells to Treg (42).”
Dose-Dependent Effect of Anti-CTLA-4 on Survival in Sepsis
Inoue, S., Bo, L., Bian, J., Unsinger, J., Chang, K., & Hotchkiss, R. S. (2011) · Shock · doi:10.1097/shk.0b013e3182168cce · Cited by 151
“Conversely, there is increasing interest in the possible therapeutic benefits of blocking CTLA-4 as a means of inhibiting immune system tolerance to tumors and thereby providing a potentially useful immunotherapy strategy for patients with cancer (8, 9).”
BackgroundResultThe interplay of effector and regulatory T cells in cancer
Roychoudhuri, R., Eil, R. L., & Restifo, N. P. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.003 · Cited by 169
“However, CTLA-4 treatment results in increased Teff:Treg cell ratios within tumors [113 ,114,115] and its efficacy, in part, requires depletion of antibody-bound Treg cells by Fcg receptor–expressing macrophages within the tumor microenvironment [116,117].”
BackgroundWatanabe, Y., Katou, F., Ohtani, H., Nakayama, T., Yoshie, O., & Hashimoto, K. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2009.12.015 · Cited by 168
Cytotoxic T-Lymphocyte–Associated Antigen-4
Salama, A. K. S., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2232 · Cited by 149
Magnuson, A. M., Kiner, E., Ergun, A., Park, J. S., Asinovski, N., Ortiz-Lopez, A., Kilcoyne, A., Paoluzzi-Tomada, E., Weissleder, R., Mathis, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810580115 · Cited by 144
CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection
Wennerberg, E., Spada, S., Rudqvist, N.-P., Lhuillier, C., Gruber, S., Chen, Q., Zhang, F., Zhou, X. K., Gross, S. S., Formenti, S. C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0449 · Cited by 155
“The ratio of CD8þ T cells to Tregs, a parameter associated with effective tumor rejection in response to immunotherapy (38), was significantly increased only in tumors ofmice treatedwith radiotherapy andCD73 blockade (Fig.”
BackgroundBudhu, S., Schaer, D. A., Li, Y., Toledo-Crow, R., Panageas, K., Yang, X., Zhong, H., Houghton, A. N., Silverstein, S. C., Merghoub, T., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aak9702 · Cited by 143
“The efficacy of many immunotherapeutic approaches that target T cell co-inhibitory and costimulatory receptors correlateswith an altered balance in the ratio of effectorT cells to Tregs in favor of the effector cells (3, 6, 7).”
BackgroundYan, T., Cui, H., Zhou, Y., Yang, B. J., Kong, P., Zhang, Y., Liu, Y., Wang, B., Cheng, Y., Li, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09255-1 · Cited by 155
Modulation of GITR for cancer immunotherapy
Schaer, D. A., Murphy, J. T., & Wolchok, J. D. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.011 · Cited by 142
“This results in an enhanced intra-tumor Teff:Treg ratio, correlating with therapeutic benefit, similar to what has been reported with OX40 and CTLA-4, [42 ,57,59].”
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Rojas, J. J., Sampath, P., Hou, W., & Thorne, S. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2009 · Cited by 141
“The schedule and doses of anti-CTLA4 antibody used were determined based on previously published pre-clinical studies (24-26).”
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 141
Villarreal, D. O., L'Huillier, A., Armington, S., Mottershead, C., Filippova, E. V., Coder, B. D., Petit, R. G., & Princiotta, M. F. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1119 · Cited by 139
“3E), further suggesting a tipping of immune balance in favor of antitumor immunity (21).”
BackgroundExperimental mouse tumour models: what can be learnt about human cancer immunology?
Dranoff, G. (2011) · Nature reviews. Immunology · doi:10.1038/nri3129 · Cited by 154
“These aspects include the importance of the intratumoural balance of effector and regulatory T cells, and the upregulation of T cell co-stimulatory molecules, such as inducible T cell co-stimulator (ICOS”
BackgroundCombination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 139
“Preclinical studies showed that subcutaneous injection of GVAX plus CTLA-4 blockade synergistically promoted tumor eradication in the B16 mouse melanoma model (response rate 80 versus 16% with GVAX alone) (79) due to an increase in CD8+ T cells and in effector T cell/Treg ratio in the tumor (80).”
BackgroundTanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
“Whereas in healthy peripheral organs Tregs constitute approximately 10 % of total CD4 T cells, this proportion is consistently increased in the tumor microenvironment, where Tregs can account for 30–50 % of CD4 T cells, depending on tumor type [3].”
BackgroundMitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3243 · Cited by 135
“Although it has been reported that anti-CTLA-4 mAb and anti-GITR mAb enhance T-cell proliferation, cytokine secretion, and CD25 expression (5, 15, 31), they have not been evaluated and compared in the same system.”
BackgroundWu, A. A., Bever, K. M., Ho, W. J., Fertig, E. J., Niu, N., Zheng, L., Parkinson, R. M., Durham, J. N., Onners, B., Ferguson, A. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1025 · Cited by 146
Hannani, D., Vétizou, M., Enot, D. P., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaïb, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.28 · Cited by 135
Pastor, F., Kolonias, D. S., McNamara, J. O., & Gilboa, E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.145 · Cited by 139
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 152
Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
Curran, M. A., & Allison, J. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3289 · Cited by 132
“Both B16-Flt3L and B16-GMCSF vaccinations are known to elicit Tregs that dampen antitumor responses (35, 36).”
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy
Sharma, N., Atolagbe, O. T., Ge, Z., & Allison, J. P. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201811 · Cited by 131
Chen, S.-H., Dominik, P. K., Stanfield, J., Ding, S., Yang, W., Kurd, N. S., Llewellyn, R. A., Heyen, J. R. R., Wang, C., Melton, Z., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003464 · Cited by 142
“MC38-bearing mice were treated with isotype (control) or mBisAb every 3–4 days starting at day 10 post-tumor implantation, and tumors and spleens were harvested at day 15, 20, or 25.”
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments
Cuzzubbo, S., Mangsbo, S. M., Nagarajan, D., Habra, K., Pockley, A. G., & McArdle, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615240 · Cited by 145
Phung, C. D., Pham, T. T., Nguyen, H. T., Nguyen, T. T., Ou, W., Jeong, J.-H., Choi, H.-G., Ku, S. K., Yong, C. S., & Kim, J. O. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.08.008 · Cited by 123
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells
Sitkovsky, M. V., Lukashev, D. E., Deaglio, S., Dwyer, K. M., Robson, S. C., & Ohta, A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.23 · Cited by 136
“Inhibition of the deleterious tumour infiltrating Tregs is considered highly desirable to improve the immunotherapy of cancer (reviewed by Shevach, 2004; Frumento et al., 2006; Quezada et al., 2006; Danese and Rutella, 2007; Wang and Wang, 2007).”
BackgroundGalectin-1 as a potent target for cancer therapy: role in the tumor microenvironment
Ito, K., Stannard, K. A., Gabutero, E., Clark, A. M., Neo, S., Onturk, S., Blanchard, H., & Ralph, S. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9388-2 · Cited by 148
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy
Pittet, M. J., Grimm, J., Berger, C. R., Tamura, T., Wojtkiewicz, G., Nahrendorf, M., Romero, P., Swirski, F. K., & Weissleder, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704460104 · Cited by 121
Immune checkpoints in cancer clinical trials
Sharon, E., STREICHER, H. Z., Goncalves, P. H., & Chen, H. X. (2014) · 癌症:英文版 · doi:10.5732/cjc.014.10122 · Cited by 125
“Researchers have established that higher Teff/ Treg ratios in both CD4-positive and CD8-positive tumor-infiltrating lymphocytes are associated with enhanced tumor eradication when CTLA4 blockade is employed in tumor models([24,25]).”
BackgroundAgarwalla, P. K., Barnard, Z. R., Fecci, P. E., Dranoff, G., & Curry, W. T. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182562d59 · Cited by 124
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wang, W., Yu, D., Sarnaik, A. A., Yu, B., Hall, M., Morelli, D., Zhang, Y., Zhao, X., & Weber, J. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-146 · Cited by 120
“CTLA-4 blockade has antitumor activity in mice, and important effects on the breaking of tolerance [6-10].”
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Furness, A. J. S., Vargas, F. A., Peggs, K. S., & Quezada, S. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.002 · Cited by 125
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
Lee, K.-W., Yam, J. W. P., & Mao, X. (2023) · Cells · doi:10.3390/cells12172147 · Cited by 117
Autophagy protects tumors from T cell–mediated cytotoxicity via inhibition of TNFα-induced apoptosis
Young, T. M., Reyes, C., Pasnikowski, E. M., Castanaro, C., Wong, C. F., Decker, C. E., Chiu, J., Song, H., Wei, Y., Bai, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb9561 · Cited by 119
Kvarnhammar, A. M., Veitonmäki, N., Hägerbrand, K., Dahlman, A., Smith, K. E., Fritzell, S., von Schantz, L., Thagesson, M., Werchau, D., Smedenfors, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0570-8 · Cited by 115
“Increased intratumoral CD8 T cell/Treg ratio has been associated with therapeutic response both in pre-clinical studies in mice [8, 32, 35], and in cancer patients [36, 37].”
BackgroundCTLA4 Expression Is an Indicator and Regulator of Steady-State CD4+FoxP3+ T Cell Homeostasis
Tang, A. L., Teijaro, J. R., Njau, M. N., Chandran, S. S., Azimzadeh, A. M., Nadler, S. G., Rothstein, D. M., & Färber, D. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1806 · Cited by 135
“However, in tumor models, the net result of antiCTLA4 treatment is an increase in tumor-specific immune responses (52, 53), although an increase in both effector and Treg numbers has been observed (54).”
BackgroundTherapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2015) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115
Onda, M., Kobayashi, K., & Pastan, I. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820388116 · Cited by 124
“Conversely, a high Teff/Treg cell ratio is associated with responses to immunotherapy (11).”
BackgroundTumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy
Escors, D. (2014) · New Journal of Science · doi:10.1155/2014/734515 · Cited by 112
“Nevertheless, it is likely that better outcomes will be expected in combination therapies [286].”
BackgroundAdvances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 127
Suryadevara, C. M., Desai, R. R., Abel, M. L., Riccione, K. A., Batich, K. A., Shen, S. H., Chongsathidkiet, P., Gedeon, P. C., Elsamadicy, A. A., Snyder, D. J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1434464 · Cited by 114
Enhanced formation and survival of CD4+CD25hiFoxp3+T-cells in chronic lymphocytic leukemia
Jak, M., Mous, R., Remmerswaal, E. B. M., Spijker, R., Jaspers, A., Yagüe, A., Eldering, E., van Lier, R. A. W., & van Oers, M. H. J. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902803677 · Cited by 130
“Moreover, in active immunotherapy it has been shown that blockade of CTLA-4 potentates anti-tumor T-cell responses, possibly by selective targeting of antitumor Treg cells [40,41].”
BackgroundHo, V. T., Vanneman, M., Kim, H., Sasada, T., Kang, Y. J., Pasek, M., Cutler, C., Koreth, J., Alyea, E., Sarantopoulos, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908358106 · Cited by 109
“Because the balance of these T-cell subsets is a critical determinant of immune-mediated tumor destruction (14, 15), a high ratio early after transplant might increase vaccination activity.”
BackgroundExpanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy
Dobrzanski, M. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00063 · Cited by 124
“…of cytoablative treatments, and have suggested that such responses are likely due to the balance between effector T cells (i.e., either CD4 or CD8) and TReg cells within treated cancer patients (Alvaro et al., 2005; Quezada et al., 2006; Hunder et al., 2008; Le and Jaffee, 2012; Liu et al., 2012a).”
Background
Metadata
- Authors
- Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Quezada, S. A.
- ORCID
- Quezada, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1935-1945
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1479425
- OpenAlex
- W2131874142
- Cited by
- 700
- References
- 50
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 44 · 2020: 35 · 2019: 37 · 2018: 41 · 2017: 46 · 2016: 29 · 2015: 41 · 2014: 41 · 2013: 39 · 2012: 38
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, GM-CSF, GVAX, tumor cell vaccine, regulatory T cells, effector T cells, B16-BL6 melanoma, antitumor immunity, Foxp3, CD8+ T cells, CD4+ T cells, tumor rejection, combination immunotherapy
- MeSH terms
- Animals, Antigens, Differentiation, Immunotherapy, Lymph Nodes, Melanoma, Experimental, Mice, Inbred C57BL, Antigens, CD, CD4 Antigens, T-Lymphocyte Subsets, Granulocyte-Macrophage Colony-Stimulating Factor, CD8 Antigens, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.